PatientsVille.com Logo

VISION BLURRED and Ranitidine

PatientsVille

VISION BLURRED Symptoms and Causes

What is high blood pressure in pregnancy?

Blood pressure is the force of your blood pushing against the walls of your arteries as your heart pumps blood. High blood pressure, or hypertension, is when this force against your artery walls is too high. There are different types of high blood pressure in pregnancy:

  • Gestational hypertension is high blood pressure that you develop while you are pregnant. It starts after you are 20 weeks pregnant. You usually don't have any other symptoms. In many cases, it does not harm you or your baby, and it goes away within 12 weeks after childbirth. But it does raise your risk of high blood pressure in the future. It sometimes can be severe, which may lead to low birth weight or preterm birth. Some women with gestational hypertension do go on to develop preeclampsia.
  • Chronic hypertension is high blood pressure that started before the 20th week of pregnancy or before you became pregnant. Some women may have had it long before becoming pregnant, but didn't know it until they got their blood pressure checked at their prenatal visit. Sometimes chronic hypertension can also lead to preeclampsia.
  • Preeclampsia is a sudden increase in blood pressure after the 20th week of pregnancy. It usually happens in the last trimester. In rare cases, symptoms may not start until after delivery. This is called postpartum preeclampsia. Preeclampsia also includes signs of damage to some of your organs, such as your liver or kidney. The signs may include protein in the urine and very high blood pressure. Preeclampsia can be serious or even life-threatening for both you and your baby.
What causes preeclampsia?

The cause of preeclampsia is not known.

Who is at risk for preeclampsia?

You are at higher risk of preeclampsia if you

  • Had chronic high blood pressure or chronic kidney disease before pregnancy
  • Had high blood pressure or preeclampsia in a previous pregnancy
  • Have obesity
  • Are over age 40
  • Are pregnant with more than one baby
  • Are African American
  • Have a family history of preeclampsia
  • Have certain health conditions, such as diabetes, lupus, or thrombophilia (a disorder which raises your risk of blood clots)
  • Used in vitro fertilization, egg donation, or donor insemination
What problems can preeclampsia cause?

Preeclampsia can cause

  • Placental abruption, where the placenta separates from the uterus
  • Poor fetal growth, caused by a lack of nutrients and oxygen
  • Preterm birth
  • A low birth weight baby
  • Stillbirth
  • Damage to your kidneys, liver, brain, and other organ and blood systems
  • A higher risk of heart disease for you
  • Eclampsia, which happens when preeclampsia is severe enough to affect brain function, causing seizures or coma
  • HELLP syndrome, which happens when a woman with preeclampsia or eclampsia has damage to the liver and blood cells. It is rare, but very serious.
What are the symptoms of preeclampsia?

Possible symptoms of preeclampsia include

  • High blood pressure
  • Too much protein in your urine (called proteinuria)
  • Swelling in your face and hands. Your feet may also swell, but many women have swollen feet during pregnancy. So swollen feet by themselves may not be a sign of a problem.
  • Headache that does not go away
  • Vision problems, including blurred vision or seeing spots
  • Pain in your upper right abdomen
  • Trouble breathing
  • Eclampsia can also cause seizures, nausea and/or vomiting, and low urine output. If you go on to develop HELLP syndrome, you may also have bleeding or bruising easily, extreme fatigue, and liver failure.

    How is preeclampsia diagnosed?

    Your health care provider will check your blood pressure and urine at each prenatal visit. If your blood pressure reading is high (140/90 or higher), especially after the 20th week of pregnancy, your provider will likely want to run some tests. They may include blood tests other lab tests to look for extra protein in the urine as well as other symptoms.

    How is preeclampsia treated?

    Delivering the baby can often cure preeclampsia. When making a decision about treatment, your provider take into account several factors. They include how severe it is, how many weeks pregnant you are, and what the potential risks to you and your baby are:

    • If you are more than 37 weeks pregnant, your provider will likely want to deliver the baby.
    • If you are less than 37 weeks pregnant, your health care provider will closely monitor you and your baby. This includes blood and urine tests for you. Monitoring for the baby often involves ultrasound, heart rate monitoring, and checking on the baby's growth. You may need to take medicines, to control your blood pressure and to prevent seizures. Some women also get steroid injections, to help the baby's lungs mature faster. If the preeclampsia is severe, you provider may want you to deliver the baby early.

    The symptoms usually go away within 6 weeks of delivery. In rare cases, symptoms may not go away, or they may not start until after delivery (postpartum preeclampsia). This can be very serious, and it needs to be treated right away.

Check out the latest treatments for VISION BLURRED

VISION BLURRED treatment research studies

Ranitidine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Ranitidine Side Effects

Dyspnoea (125)
Anaphylactic Reaction (77)
Hypotension (71)
Diarrhoea (67)
Nausea (65)
Vomiting (62)
Urticaria (59)
Abdominal Pain (46)
Dizziness (43)
Malaise (43)
Cardiac Arrest (40)
Pain (39)
Loss Of Consciousness (37)
Fatigue (36)
Angioedema (35)
Confusional State (34)
Renal Failure Acute (33)
Pruritus (32)
Headache (32)
Chest Pain (31)
Abdominal Pain Upper (29)
Overdose (27)
Bradycardia (27)
Rash (27)
Pyrexia (25)
Hypersensitivity (24)
Dyspepsia (23)
Circulatory Collapse (23)
Chest Discomfort (22)
Erythema (21)
Thrombocytopenia (21)
Gastrooesophageal Reflux Disease (21)
Product Quality Issue (21)
Weight Decreased (20)
Burning Sensation (20)
Alanine Aminotransferase Increased (20)
Paraesthesia (20)
Cholelithiasis (20)
Dysgeusia (19)
Neutropenia (19)
Cough (19)
Flushing (19)
Hypertension (19)
Tubulointerstitial Nephritis (18)
Condition Aggravated (17)
Feeling Abnormal (17)
Depression (17)
Vision Blurred (17)
Agitation (16)
Heart Rate Increased (16)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Emotional Anxciety then chest pain, jaw pain on left side and headaches, I am not taking it no more. there has to be something else less tramatising to my system. It was bad enugh that i was at work when the emotional anxiety hit. not cool at all.

<strong>gracia por la informacion</strong>

*DONT_KNOW* guess that's an honest answer

Has there been any evidence linking ranitidine to lower back or hip problems?

Is Histac 150 a pain reliever for slip disc backache?

Will Marinol further damage, an already diseased liver

fROM THE DAY i GOT THE INJECTION aCLASTA, i AM FEELING GIDDY AND HAVE LOST MY VISION. w WHAT IS YOUR RESPONSIBILITY ABOUT THIS fROM THE DAY i GOT aCLASTA INJECTION, i AM FEELING

Blurred vision, giddiness,Tiredness,Swelling on feet and hands

M 23 of age.. And via consultant i am taking seroxat(20mg)... about two mouths ago..but still sharp headache occured daily n morning...plus my vision gets blurred n morning..don't nw why..its really annoying... Lik eithr its a medicn side effects o

can advagraf makke you look like you are pregnant? Can this drug affect your eye site--blurry vision

Started taking Bystolic 5mg on Thursday for tachycardia. Sunday, had blurred vision. (Was driving and it was so bad that the interstate signs were blurred!) Stopped medicine and called doctor on Monday. Tuesday, called back because nobody saw f

&lt;b&gt;Describe Your Seroxat Experience Here:&lt;/b&gt;Stomach and wierd vision and feeling tired

I was given Celestene by a GP in Frace for bronchial problems/ashma - 4mg for 10 days. It gave me really irritated red skin with spots, overy sensitive skin to my face which tingled when touched, stomach problems and blured vision

<span style='color: #808080;'><b>My son complained of not being able to see to well so I took him to lenscrafters to check his vision since he wore glasses before and had lost them. No big deal I thought, anyway they took some t

<span style='color: #808080;'><b>What do You think about Vision impairment and blindness?</b>

45 Male on Enbrel 4 + years , My condition is all but gone and I really use no other meds now. Expect a dry cough , Poor night vision ,Memory loss ,and in some cases (345) amniesia. IHAVE noticed a difficulty in learning new&am

VISION BLURRED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Comparison of Pantoprazole and Ranitidine in Dyspepsia
Condition: Dyspepsia
Interventions: Drug: Pantoprazole;   Drug: Ranitidine
Outcome Measures: Visual analogue scale score;   Need for additional drug
2 Recruiting TPI 287 in Breast Cancer Metastatic to the Brain
Condition: Breast Cancer
Interventions: Drug: TPI 287;   Drug: Dexamethasone;   Drug: Benadryl;   Drug: Ranitidine
Outcome Measure: Overall Response Rate
3 Recruiting Treatment of Orthostatic Hypotension in Autonomic Failure
Conditions: Autonomic Failure;   Orthostatic Hypotension
Interventions: Drug: Atomoxetine;   Drug: Acarbose;   Drug: Pyridostigmine Bromide;   Drug: Yohimbine;   Drug: Midodrine HCl;   Drug: placebo;   Drug: Modafinil;   Drug: Octreotide;   Other: water intake;   Drug: Diphenhydramine Hydrochloride;   Drug: Ranitidine HCL;   Drug: Tranylcypromine;   Drug: Ergotamine/ Caffeine;   Drug: Celecoxib;   Drug: Pseudoephedrine;   Drug: Methylphenidate;   Drug: Indomethacin;   Drug: Ibuprofen;   Drug: Oxymetazoline 0.05% nasal solution;   Dietary Supplement: Bovril;   Drug: Acetazolamide;   Drug: Rivastigmine tartrate;   Drug: Carbidopa/levodopa;   Device: Inflatable abdominal binder;   Device: inflatable abdominal binder (sham)
Outcome Measures: Increase in seated systolic blood pressure 1-hr post drug compared to baseline.;   Increase in standing time 1-hr post drug compared to baseline
4 Not yet recruiting The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux
Conditions: Eustachian Tube Dysfunction;   Laryngopharyngeal Reflux
Interventions: Drug: Omeprazole;   Drug: Ranitidine;   Drug: Pantoprazole;   Procedure: 24-Hour Diagnostic pH-Probe Test;   Procedure: Laryngoscopy
Outcome Measure: Evidence of laryngopharyngeal reflux in patients complaining of ear fullness/pressure/pain
5 Recruiting Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents
Conditions: Pharmacokinetics;   Voriconazole
Intervention: Drug: Midazolam/Ranitidine/Esomeprazole
Outcome Measures: Voriconazole steady-state pharmacokinetics;   Voriconazole drug metabolizing enzyme activity
6 Recruiting Clinical Trial Corticoids For Empyema And Pleural Effusion In Children
Conditions: Parapneumonic Pleural Effusion;   Empyema
Interventions: Drug: Dexamethasone;   Drug: Placebo
Outcome Measures: time to resolution;   number of children with complications.;   Number of children with complications attributable to corticoids
7 Unknown  Mechanisms of N-acetylcysteine Mediated Vascular Adverse Effects
Condition: Poisoning
Interventions: Drug: Chlorphenamine and Ranitidine;   Drug: Paracetamol
Outcome Measures: Attenuation of NAC induced vasodilatation by histamine antagonists (H1 and H2 antagonists) and/or paracetamol;   Inhibition of the inflammatory cascade contributes to a paracetamol mediated protective role against NAC adverse reactions.
8 Unknown  Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital
Condition: Dyspepsia
Intervention: Procedure: gastroscopic examination
Outcome Measures: Incidence of H. pylori Clarithromycin resistance gene;   Characteristic of H. pylori clarithromycin resistant gene mutation
9 Unknown  Efficacy of Acetilcysteine in 'Rescue' Therapy for Helicobacter Pylori Infection. Pilot Study
Condition: Helicobacter Pylori Infection
Interventions: Drug: Group A: NCA 600 mg+antibiotics;   Drug: Group B: antibiotic treatment (control)
Outcome Measure: To evaluate the usefulness of NAC as pre-treatment attempt associated with a culture-guided antibiotic therapy as rescue therapy after multi-attempts antibiotic failure
10 Recruiting Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme
Condition: Glioblastoma Multiforme (GBM) WHO Grade IV
Intervention: Drug: Cabazitaxel
Outcome Measures: Response including SD, PR or CR determined by MRI (modified RANO criteria);   Overall and progression-free survival;   Safety and tolerability;   Pharmacokinetics data concerning drug interactions (i.e. CYP3A induction);   Quality of life and neurocognitive functioning
11 Recruiting Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: carboplatin
Outcome Measures: To determine if patients have lower rates of hypersensitivity reactions compared to those treated with standard infusion carboplatin.;   Determine the rate of successful planned treatment completion of carboplatin in each group;   Perform a cost-identification analysis of extended infusion carboplatin to estimate the cost per hypersensitivity reaction prevented.;   Perform exploratory analyses to correlate hypersensitivity rate to history of atopy, prior drug allergies, number of lifetime platinum cycles, duration since last platinum, and concomitant chemotherapy agent.
12 Not yet recruiting Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)
Condition: Breast Neoplasms
Interventions: Drug: Vintafolide 2.5 mg;   Drug: Paclitaxel 80 mg/m^2;   Drug: Etarfolatide;   Drug: Folic acid;   Drug: Premedication for Paclitaxel
Outcome Measures: Progression Free Survival (PFS);   Objective Response Rate (Complete Response [CR] + Partial Response [PR]);   Clinical Benefit Rate (CR + PR + Stable Disease [SD] for >=6 months);   Overall Survival (OS)
13 Recruiting MAGIC vs. CROSS Upper GI. ICORG 10-14, V3
Conditions: Adenocarcinoma of the Oesophagus;   Adenocarcinoma of the Oesophago-gastric Junction;   Oesophageal Tumours;   Junctional Tumours;   Oesophageal Cancer
Interventions: Drug: Epirubicin;   Drug: Cisplatin;   Drug: 5 Flourouracil/ Capecitabine;   Radiation: (41.4 Gy/23 fractions);   Drug: Paclitaxel;   Drug: Carboplatin
Outcome Measure: Overall survival
14 Recruiting Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
Condition: Neoplasms
Interventions: Drug: Paclitaxel;   Drug: Copanlisib (BAY80-6946)
Outcome Measures: Adverse event collection;   Maximum tolerated dose, measured by adverse event profile;   Pharmacokinetics characterized by Cmax of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by Cmax/D of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by tmax of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by AUC(0-tlast) of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by AUC (if possible) of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by AUC/D of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by half-life of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by partial AUC values [eg, AUC(0-25)] of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by clearance of BAY80-6946 (and its metabolite(s), if needed);   Pharmacokinetics characterized by volume of distribution of BAY80-6946 (and its metabolite(s), if needed);   Estimation of percent of dose excreted [unchanged or as metabolites, if relevant) renally during 0 - 25 h after start of BAY80-6946 infusion (AE,ur(0-25)] (for Cohort 4 only);   Pharmacokinetics characterized by Cmax of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by tmax of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by AUC(0-t) of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by AUC of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by half-life of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by clearance of Paclitaxel and 6-OH paclitaxel;   Pharmacokinetics characterized by volume of distribution (If possible and needed) of Paclitaxel and 6-OH paclitaxel;   Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing Cmax of Cycle 1 Day 1 and Cycle 1 Day 15;   Effect of BAY80-6946 on paclitaxel PK will be assessed by comparing AUC(0-tlast) of Cycle 1 Day 1 and Cycle 1 Day 15;   Number of patients with mutational status;   Tumor Response as measured by RECIST 1.1 criteria
15 Recruiting Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Conditions: Non-small Cell Lung Cancer;   Advanced Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Hydroxychloroquine;   Drug: Bevacizumab
Outcome Measures: Antitumor activity, as measured by tumor response rate of hydroxychloroquine, paclitaxel, carboplatin, and bevacizumab (for eligible patients) in patients with advanced or recurrent NSCLC cancer;   Time to progression;   Survival;   Overall survival;   Toxicity of hydroxychloroquine, paclitaxel, carboplatin, and bevacizumab (for eligible patients) in patients with advanced or recurrent NSCLC cancer
16 Unknown  Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
Conditions: Brain and Central Nervous System Tumors;   Extragonadal Germ Cell Tumor;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions: Biological: filgrastim;   Biological: lenograstim;   Biological: pegfilgrastim;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: ifosfamide;   Drug: paclitaxel
Outcome Measures: Maximum tolerated dose of gemcitabine hydrochloride when administered with TIP chemotherapy comprising paclitaxel, ifosfamide, and cisplatin with growth factor support (phase I);   Response rates (phase I);   Failure-free survival (phase I);   Utility of positron emission tomography scanning after Gem-TIP chemotherapy (phase I);   Degree of dose intensification achieved with Gem-TIP chemotherapy relative to a previous Medical Research Council study with TIP alone (phase II)